PHC and JCR Pharma Release Second Update for "Meron Diary" Growth Hormone Treatment App

02 October 2023 | Monday | News

PHC CORPORATION Diagnostic Reagents Division (Head Office: Minato-ku, Tokyo, President & CEO: Shinro Nakamura, hereinafter "PHC IVD") and JCR Pharma Co., Ltd. (Headquarters: Ashiya City, Hyogo Prefecture, Chairman & President: Makoto Ashida, hereinafter referred to as "JCR Pharma") is pleased to announce the launch of the electric growth hormone injection device "Glow Jector Duo®(*1)and "Glow Jector L®(*2)Compatible with the growth hormone treatment medication management application software "Meron Diary®(*3)We would like to inform you that the function of " has been updated. An updated version of this application has been released on the App Store and Google Play from October 2023, 10.
Image Source : Public Domain

Image Source : Public Domain

Jointly developed by PHC IVD and JCR Pharma and released for the first time in October 2020, "Meron Diary" is a smartphone application that can wirelessly receive and check the injection history recorded inside the main unit of the "Gloujector" series. By inputting the injection site record and the patient's height and weight data, the growth curve can be automatically created and displayed, and PDF data can be sent to a PC by email. In addition, the "fun function" using avatars aimed at relieving the tension of patients with injections and promoting active treatment®®(*4)We support patients, their guardians, and healthcare professionals with IoMT (Internet of Medical Things) technology.

With this update, "Meron Diary" can also be used with the newly released "Glow Jector Duo" in September 2023. In addition, a "simple mode" dedicated to treatment support functions has been added with a smart main screen display, and it can be switched from the conventional main screen display "normal mode". In addition, in "Normal Mode", avatar items with fun functions have been expanded. ®®

By using "Meron Diary" together with "Gloujector Duo" and "Gloujector L", we will contribute to the lifestyle of patients of all ages, support long-term treatment, and improve medication adherence. ®®®

Updates to "Meron Diary"® ─

  • The function of "Meron Diary" can also be used with the "Glow Jector Duo" newly released in September 2023 ®®
  • In addition to the "normal mode" of the screen display centered on the mascot character familiar from "Meron Diary", it is equipped with a "simple mode" with a smart screen display that can be used by a wider range of ages. ®
  • Display drug replacement history in the app's injection history calendar
  • Increase the number of registered accounts from 30 to 50 to allow healthcare professionals to monitor more patients' treatment records
  • 20 avatar items added to the fun function of "Normal Mode"
  • The "Collection Screen" that allows you to check all avatar items acquired in the past and the "Shashin" function that allows you to archive the avatars you have created are newly installed, and the results of continued treatment are visualized.

Hiroyuki Tokunaga, Director and General Manager of the Diagnostic Reagents Division at PHC Co., Ltd., said:
"By integrating sophisticated manufacturing with digital technology, we aim to provide a solution that allows patients to easily visualize and manage their own health information at any time, not only in hospitals and clinics, but also from home. We expect that this will lead to effective medication treatment for patients. We will continue to contribute to the realization of higher quality of medical care by helping to improve patients' QOL and providing best-in-class healthcare solutions that meet the challenges of healthcare professionals." 

Toru Ashida, Senior Managing Director and General Manager of the Sales Division at JCR Pharma Co., Ltd., said: "Through the 'Glowjector' series and 'Meron Diary,' we have been conducting product information provision activities, research, and development to meet the needs of patients treated with the human growth hormone preparation 'Glowject.' We are very pleased that the application can be used to grow patients, and we hope that it will be a step forward in the further development of digital transformation in the healthcare field. We will continue to provide a wide range of options for growth hormone treatment and contribute to the development of pediatric medicine." ®®®®


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in